In the last trading session, 1.1 million Regenxbio Inc (NASDAQ:RGNX) shares changed hands as the company’s beta touched 1.34. With the company’s per share price at $6.72 changed hands at -$0.21 or -3.03% during last session, the market valuation stood at $332.95M. RGNX’s last price was a discount, traded about -328.57% off its 52-week high of $28.80. The share price had its 52-week low at $6.56, which suggests the last value was 2.38% up since then.

Analysts gave the Regenxbio Inc (RGNX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.45. If we narrow down to specifics, the data shows that 0 out of 6 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended RGNX as a Hold, 6 felt it is a Buy and 0 rated the stock as Underweight.

Regenxbio Inc (NASDAQ:RGNX) trade information

Instantly RGNX was in red as seen at the end of in last trading. With action -11.35%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -13.07%, with the 5-day performance at -11.35% in the red. However, in the 30-day time frame, Regenxbio Inc (NASDAQ:RGNX) is -14.72% down.

The consensus price target for the stock as assigned by Wall Street analysts is 26, meaning bulls need an upside of 74.15% from its current market value. According to analyst projections, RGNX’s forecast low is 18 with 39 as the target high. To hit the forecast high, the stock’s price needs a -480.36% plunge from its current level, while the stock would need to soar -167.86% for it to hit the projected low.

The 2025 estimates are for Regenxbio Inc earnings to increase by 21.49%, but the outlook for the next 5-year period is at 26.49% per year.

RGNX Dividends

Regenxbio Inc is expected to release its next quarterly earnings report in March.

VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 11.1818% or 5.11 million shares worth $59.83 million as of 2024-06-30.